The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
Although some tumors lack aneuploidy or have few extra chromosomal copies, others have a slew of mutations.
All patients enrolled in the phase 3 study had metastatic CRC characterized as MSI-H/dMMR, a biomarker found in only approximately 5% of these tumors.
Antibody-drug conjugate trastuzumab deruxtecan demonstrated promising efficacy against relapsed, metastatic, HER2+ CRC according to results from a phase 2 trial.
This study focused on a cohort of nonelderly Medicaid beneficiaries with stage IV breast or colorectal cancer who resided in New Jersey.
High adherence to the at-home, stool-based screening test is a positive sign, but its impact on survival outcomes is still unclear.
Researchers find a type of E.coli often found in the normal gut microbiome secretes a genotoxic substance, which leaves a mutational fingerprint linked to some cases of colorectal cancer.
Almost all who met criteria for early screening could have initiated screening before age of diagnosis.
Patients older than 25 years have significantly higher rates of OS and RFS at 3 and 5 years compared with patients younger than 25.
